Alnylam Assist™: Patient Support Program

Alnylam Assist™ will provide support for your patients as they begin treatment with AMVUTTRA

Our Case Managers are here to help your patients.

Call Us:

1-833-256-2748

Monday - Friday, 8am - 6pm

Enroll Your Patients

How Alnylam Assist™ Can Help

Alnylam Assist is committed to providing your patient support throughout treatment with AMVUTTRA. Alnylam Assist offers support services to your patient in 4 key areas

Alnylam Assist® - Understanding Your Benefits

Benefit Verification

Help determining
patient-specific coverage

Alnylam Assist® - Financial Assistance Options

Financial Assistance

Information about patients'
eligibility for financial assistance

Alnylam Assist® - Disease and Treatment Education

Patient Education

Disease and product education
for patients and families

Alnylam Assist® Reimbursement Support Icon

Treatment Access

Education about the prior authorization,
claims, and appeals processes

Get Started

Forms and Documents

Download the materials below for more information about Alnylam Assist™

See All Forms and Documents ›

Alnylam Assist® - Downloadable PDF

Healthcare Professionals

Alnylam Assist™ Support Services
Overview Brochure

Download

Alnylam Assist® - Downloadable PDF

Patients + Caregivers

Alnylam Assist™ Brochure
 

Download

Alnylam Assist® Case Managers

Enroll Your Patients

After deciding to prescribe your patient AMVUTTRA, consider enrolling your patient in Alnylam Assist™.

Alnylam Assist® Case Managers

1-833-256-2748

Monday - Friday, 8am - 6pm

Enroll Your Patients

Enrolling Your Patients

Together with your patient
(in office)

Alnylam Assist® electronic Start Form icon

Electronic Start Form

Begin Here ›

or

Alnylam Assist® Start Form - To Print And Fax

Print
& Fax

Download Form ›

Initiate then send to patient
(via email)

Alnylam Assist® Start Form - To Email To Patient

DocuSign eSignature

Begin Here ›

HCP triangle

IMPORTANT SAFETY INFORMATION

Reduced Serum Vitamin A Levels and Recommended Supplementation
AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions
The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

INDICATION

AMVUTTRA® (vutrisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.